Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: No significant benefits - Results of the Match study;Absence de bénéfice significatif de l'adjonction d'aspirine au clopidogrel en prévention secondaire après un accident ischémique cérébral - Résultats de l'étude Match

Presse Medicale

Volumn 35, Issue 4 II, 2006, Pages 679-682

  Calvet, David ^a   Touzé, Emmanuel ^a   Mas, Jean Louis ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; DRUG DERIVATIVE; TICLOPIDINE;

ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; DEATH; DIABETES MELLITUS; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE; BRAIN INFARCTION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; EVALUATION; FOLLOW UP; MULTICENTER STUDY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; TIME;

ASPIRIN; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEMORRHAGE; HOSPITALIZATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PATIENT SELECTION; PLACEBOS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TICLOPIDINE; TIME FACTORS;

EID: 33646901048     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(06)74662-0     Document Type: Article

References (23)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-anlysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 524: 71-86.
2. Caprie Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (Caprie). Lancet. 1996; 348: 1329-39.
3. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989; 2: 1215-20.
4. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dypiridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurological Sciences. 1996; 143: 1-13.
5. Leonardi-Bee J, Bath PMW, Bousser MG, Dalavos A, Diener HC, Guiraud-Chaumeil B et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events. Stroke. 2005; 36: 162-8.
6. Ringleb P, Bhatt D, Hirsch A, Topol E, Hacke W, on behalf of the Caprie investigators. The benefit of clopidogrel over aspirin is amplified in patients with a prior history of ischemic events. Stroke. 2004; 35: 528-32.
7. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002; 90: 625-8.
8. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.
9. Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411-20.
10. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (Match): randomized, double blind, placebo-controlled trial. Lancet. 2004; 364: 331-7.
11. Algra A, Van Gijn J. Cumulative meta-analysis of aspirin after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999; 66: 255.
12. Rothwell PM. Lessons from Match for future randomized trials in secondary prevention of stroke. Lancet. 2004; 364: 305-30.
13. Bogousslavky J, Van Melle G, Regli F for the Lausanne stroke registry group. The Lausanne stroke registry: analysis of 1000 consecutive patients with first stroke. Stroke. 1988; 19: 1083-92.
14. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke, The german stroke data bank. Stroke. 2001; 32: 2559-66.
15. Lovett JK, Coull A, Rothwell PM, on behalf of the Oxford vascular study. Early risk of recurrent stroke by aetiological subtype: implications for stroke prevention. Neurology. 2004; 62: 569-74.
16. Gorter JW, for the Stroke Prevention In Reversible Ischaemia Trial (SPIRIT) and European Atrial Fibrillation Trial (EAFT) groups. Major bleeding during anticoagulation after cerebral ischaemia: patterns and risk factors. Neurology. 1999; 53: 1319-27.
17. Arguizan C. Pathologies vasculaires cérébrales du diabétigue. Arch Mal Cœur. 2004; 97: 29-32.
18. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003; 26: 3264-72.
19. Amarenco P, Donnan GA. Shoud the Match results be extrapolated to all patients and affect ongoing trials evaluating clopidogrel plus aspirin? Stroke. 2004; 35: 2606-8.
20. Hankey G, Eikelboom JW. Adding aspirin to clopidogrel after TIA and ischemic stroke. Benefits do not match risks. Neurology. 2005; 64: 1117-21.
21. Bhatt DL, Topol EJ, on behalf of the CHARISMA executive committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Am Heart J. 2004; 148: 263-8.
22. Chan FKL, Ching JYL, Hung LCT, Wong VWS, Leung VKS, Kung NNS et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Eng J Med. 2005; 352: 238-44.
23. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004; 35: 175-8.